Annual cost of stable coronary artery disease in France: A modeling study
Autor: | Olivier Dubourg, Kevin Zarca, Nicolas Danchin, Thibaut Caruba, Brigitte Sabatier, Karine Chevreul, Benjamin Cadier, Yves Juillière |
---|---|
Jazyk: | angličtina |
Předmět: |
Male
Médicaments Time Factors National Health Programs Cost-Benefit Analysis medicine.medical_treatment Coronary artery disease Recurrence Models Cause of Death Myocardial infarction Coronary Artery Bypass Cause of death Drug-Eluting Stents Health Care Costs General Medicine Middle Aged Models Economic Treatment Outcome surgical procedures operative Metals Cardiology Female Stents France Costing study Drug Cardiology and Cardiovascular Medicine medicine.medical_specialty Revascularisation Prosthesis Design Revascularization Drug Costs Coûts Percutaneous Coronary Intervention Cost Savings Internal medicine medicine Humans Angina Stable cardiovascular diseases Aged Angor stable business.industry Percutaneous coronary intervention Stent Cardiovascular Agents medicine.disease Modélisation Chronic Disease Cardiovascular agent Emergency medicine Conventional PCI Health Expenditures business |
Zdroj: | Archives of Cardiovascular Diseases. (11):576-588 |
ISSN: | 1875-2136 |
DOI: | 10.1016/j.acvd.2015.06.006 |
Popis: | Background Few studies have analyzed the cost of treatment of chronic angina pectoris, especially in European countries. Aim To determine, using a modeling approach, the cost of care in 2012 for 1 year of treatment of patients with stable angina, according to four therapeutic options: optimal medical therapy (OMT); percutaneous coronary intervention with bare-metal stent (PCI-BMS); PCI with drug-eluting stent (PCI-DES); and coronary artery bypass graft (CABG). Methods Six different clinical scenarios that could occur over 1 year were defined: clinical success; recurrence of symptoms without hospitalization; myocardial infarction (MI); subsequent revascularization; death from non-cardiac cause; and cardiac death. The probability of a patient being in one of the six clinical scenarios, according to the therapeutic options used, was determined from a literature search. A direct medical cost for each of the therapeutic options was calculated from the perspective of French statutory health insurance. Results The annual costs per patient for each strategy, according to their efficacy results, were, in our models, € 1567 with OMT, € 5908 with PCI-BMS, € 6623 with PCI-DES and € 16,612 with CABG. These costs were significantly different (P |
Databáze: | OpenAIRE |
Externí odkaz: |